Who’s at greater risk for long-COVID? New study sheds light on vulnerable demographics

A study analyzing 134,444 participants from BRFSS and NHIS reveals that 21.5% and 17.1% respectively suffer from long-COVID, with higher risks in middle-aged, female, Hispanic individuals, those with less education, and residents of certain areas.

Samsung Bio inks largest deal yet worth $1.24B with unnamed Asian pharma

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 23, 2024

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 20, 2024

Genentech updates spinal muscular atrophy effort with new design, social media and ‘Real Talk’

Genentech is adding to its community co-created spinal muscular atrophy campaign called “SMA My Way” with new content and an updated look. The update includes

August 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.